Home » Consulting Services » Business and Data Analysis »

Business and Data Analysis

PHSL uses its vast industry experience along with analysis techniques and financial modeling to solve your toughest business problems. We analyze your situation from different points of view and identify opportunities or potential problems before they occur. Prior to your investment in a new business process or program, let PHSL model and assess its impact on your financial results.

View our case studies related to business and data analysis:

340B Compliance Review

Accounting Firm Required Pharmacy Expertise

Assessment of Specialty Generics Contract with PBM

Client Selects Copay Reduction Program

Determining Competitive Market Landscape

Drug Resources Made Available via Manufacturer’s Website

Generic Competition Studied to Determine Effects on Brand Drug

Generic Market Forecasting

Health Systems Seeks Insight on Increasing Biosimilar Adoption Rate

Industry Monitoring, Research, & Analysis Used as a Vital Decision Resource

Manufacturer Seeks Pre-Launch Rebate Level Forecasting

Medicare PDP Develops Community Pharmacy MTM Program

Payer Reject Rate for Drug Drastically Reduced After PHSL Analysis

PBM Contract Variance Analysis

PBM Positions Itself for Increased Rebate Yield

PHSI Helps PBM Develop a Pharmacy Network Contracting Strategy

PHSI Helps Supermarket Chain Move Toward Providing Pharmaceutical Care

PHSL Analyzes Data to Save Retail Pharmacy in Drug Costs

Proactive Response to Loss of Brand Patent Protection

Rebate Contracting Consolidation Process Directed by PHSI

Research Updates Brand Designation in Drug Databases

Seasonal-Use Product Reimbursement Trend Analysis

Specialty Drug Reimbursement by Pharmacy Type

Stakeholder Financial Perspectives for Brand Product Reimbursement

U&C Pricing Strategy Critical for Chain Expansion

Validation of Pharmacy Payment Methodology versus NADAC

May 2023 Question of the Month

Which type of project(s) could you or your organization most benefit from in 2023?

Future forecast: 0%

Competitor comparison: 20%

Contract variance analysis: 20%

Historical trend analysis: 20%

Legislative/regulatory impact: 0%

Procurement cost/savings: 20%

Stakeholder program impact: 20%

April 2023 Question of the Month

In July 2022, the FDA proposed expanding the NDC to a uniform 12 numeric digit format to accommodate future needs when all options using the current formats have been exhausted. Alternative options shared by the industry have asked the FDA to consider retaining the current NDC formats and allow the use of alpha characters when all numeric options have been exhausted.

Which of the following transition types is your organization prepared for in the next 5 years?

Make the transition to alphanumeric using the current NDC formats: 70%

Make the transition to the 12-digit numeric format: 20%

Make the transition to neither option: 10%

Make the transition to either option: 0%

March 2023 Question of the Month

What information would you most like to gain from an Online Listening Assessment for a particular drug therapy or device? (Multiple selections allowed)

Prescribing & Dispensing Concerns: 25%

Competitor Comparisons: 25%

Prescribing Information Alignment: 17%

Coverage & Reimbursement: 17%

Patient Affordability: 8%

Misinformation: 8%

Disease State Concerns: 0%